Xintela
0,281 SEK +2,55%1 investor følger denne virksomhed
Xintela is active in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.
Omsætning
80 t
EBIT %
-71.550 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
XINT
Daglig lav / høj pris
0,262 / 0,293
SEK
Markedsværdi
159,33 mio. SEK
Aktieomsætning
56,59 t SEK
Volumen
204 t
Seneste videoer
Finanskalender
Generalforsamling
08.05.2024
Delårsrapport
24.05.2024
Delårsrapport
30.08.2024
Delårsrapport
22.11.2024
Årsrapport
28.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Flerie Invest AB | 54,2 % | 54,2 % |
Avanza Pension | 5,0 % | 5,0 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Xintela AB, Investor Day, 2024
Västra Hamnen Market Focus: Xintela: Awaiting results in trials and discussions
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools